Amarantus Bioscience Holdings Inc (AMBS)

[Chelby84]

News for 'AMBS' - (Amarantus Posts New White Paper to Its Web Site)


May 06, 2013 (Close-Up Media via COMTEX) -- Amarantus BioScience Holdings,
Inc., a biotechnology company discovering and developing treatments and
diagnostics for diseases associated with neurodegeneration and apoptosis, has
posted to its Web site a White Paper titled "A Review of MANF Literature:
Implications for the Development Program of Amarantus Bioscience Holdings."

"This extensive report on our lead therapeutic MANF is valuable to a number of
audiences, including life science research professionals, potential development
partners, and investors as they conduct due diligence to better understand the
breadth of the technology," said Amarantus Chief Executive Officer Gerald
Commissiong. "It is the most comprehensive discussion of the properties and
potential of MANF, and we believe it will significantly enhance understanding of
our MANF therapeutic program."

Prepared by the consulting firm NeuroAssets, the 41-page report covers MANF's
protein structure and cellular activities; studies related to Parkinson's
disease, stroke, myocardial infarction and traumatic brain injury; and the
potential for further development of MANF, the Company noted in a release.

Amarantus said that MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)
is believed to have broad potential because it is a naturally-occurring protein
produced by the body for the purpose of reducing and preventing apoptosis (cell
death) in response to injury or disease, via the unfolded protein response. By
manufacturing MANF and administering it to the body, Amarantus is seeking to use
a regenerative medicine approach to assist the body with higher quantities of
MANF when needed. Amarantus is the front-runner and primary holder of
intellectual property (IP) around MANF, and is initially focusing on the
development of MANF-based protein therapeutics. MANF's current lead indication
is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI).
Future indications may include myocardial infarction and certain rare and
ultra-rare orphan diseases for which MANF is currently being evaluated.

NeuroAssets identifies and manages the development of neuroscience assets that
focus on diseases of the nervous and muscle systems. NeuroAssets was founded by
David A. Lowe PhD, based on his international experience of Nervous System R&D
in Pharma, Biotech and Venture Capital Companies. The company is based in Vevey
on Lake Geneva, Switzerland, and works with business partners in the U.S.,
Europe, Middle East and Asia.

White Paper:

http://ir.stockpr.com/amarantus/scientific-publications